Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia / 中国医学科学杂志(英文版)
Chinese Medical Sciences Journal
;
(4): 168-172, 2002.
Article
Dans Anglais
| WPRIM
| ID: wpr-244855
ABSTRACT
<p><b>OBJECTIVE</b>The efficacies of the selective 5-hydroxytryptamine3 (5-HT3) antagonists--ramosetron (0.3 mg) and granisetron (3 mg) in treating acute chemotherapy-induced digestive system dysunction were compared.</p><p><b>METHODS</b>A total of 111 patients were enrolled in a single-blind, randomised crossover study; with data from 98 were used to assess efficacy and data from 110 to assess the safety profile. Ramosetron or granisetron was given intraveneously 15 min befire chemotherpy.</p><p><b>RESULTS</b>The ability of ramosetron to prevent emesis, nausea and anorexia was similar to granisetron during the first 6 h following the administration of chemotherapy, ciplatin or doxorubicin. However, during the first 24 h after chemotherapy, significant differences between ramosetron and granisetron appeared emetic episode (P = 0.068), nausea (P = 0.006), and anorexia (P = 0.048) remained lower in ramosetron-treated patients. The safety profile of ramosetron was similar to that of granisetron and adverse events in both groups were generally mild and transient.</p><p><b>CONCLUSION</b>Ramosetron is more potent and longer-lasting than granisetron in preventing chemotherapy-induced digestive disturbances.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Antisérotonines
/
Benzimidazoles
/
Vomissements d'anticipation
/
Anorexie
/
Doxorubicine
/
Méthode en simple aveugle
/
Cisplatine
/
Granisétron
/
Études croisées
/
Utilisations thérapeutiques
Type d'étude:
Essai clinique contrôlé
Limites du sujet:
Adolescent
/
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Chinese Medical Sciences Journal
Année:
2002
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS